1910 Genetics, a Boston, MA-based biotechnology company advancing small and large molecule drug discovery with a multimodal AI platform empowered by laboratory automation, received an investment from Accenture Ventures.
The amount of the deal was not disclosed.
The company intends to use the funds to expand operations and its development efforts.
Founded by CEO Jen Nwankwo, 1910 Genetics is a small and large molecule drug discovery company providing multimodal AI platform empowered by laboratory automation. It integrates AI that leverages federated learning alongside three proprietary data streams to deliver novel drug candidates and software solutions to biopharma and tech partners, and advance its internal pipeline for neurological, autoimmune diseases, and cancer. It recently established a commercial partnership with Microsoft to bring our ITO™ platform to biopharma companies at scale.
In conjunction with this announcement, Dr. Petra Jantzer and Tom Lounibos will join the Business Advisory Board of 1910, and Dr. Kailash Swarna, a managing director in Life Sciences at Accenture, and Dr. Cecil Lynch, Biomedical Informatics lead at Accenture, will join the Technology Advisory Board of 1910.
As part of this investment, Accenture and 1910 will collaborate to combine tailored solutions and scalable infrastructure to help clients in the biopharma industry accelerate drug target identification, reduce costs, and deliver better, more affordable therapies to patients.
1910 was launched in 2021 with a combined seed and Series A funding of $26.1M from M12-Microsoft’s Venture Fund, Playground Global, OpenAI’s Sam Altman, FoundersX Ventures, and other investors.
